Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 4 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Cellartgen Inc. has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 4 distinct examiners and 4 distinct art units, so the pending work spans several examination assignments while one assignment covers more than one matter.
THUESON, HANNA MARIE is the busiest examiner, with 2 pending matters. That examiner relationship is the clearest point for coordinated claim strategy and response planning, while the remaining matters require separate tracking across their assigned examiners and art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (33%) |
| §112 only | 1 (17%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| THUESON, HANNA MARIE | 2 | 76.7% | +28.2% |
| ZHU, JIANJIAN | 1 | 58.1% | +82.5% |
| KIPOUROS, HOLLY MICHAELA | 1 | 69.8% | +21.3% |
| MELLER, MICHAEL V | 1 | 47.2% | +28.0% |
| SCHUBERG, LAURA J | 1 | 23.6% | +37.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18355798 | DECELLULARIZED TISSUE-DERIVED EXTRACELLULAR MATRIX FUNCTIONALIZED WITH PHENOL DERIVATIVE AND USE THEREOF | THUESON, HANNA MARIE | — |
| 18347763 | ADIPOSE EXTRACELLULAR MATRIX-DERIVED SCAFFOLD FOR CULTURING ORGANOID AND PREPARING METHOD THEREOF | THUESON, HANNA MARIE | — |
| 18324601 | TISSUE GELL FOR TRANSPLANTATION USING DECELLULARIZED EXTRACELLULAR MATRIX AND METHOD OF PREPARING THE SAME | SCHUBERG, LAURA J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18515269 | NON-ALCOHOLIC FATTY LIVER ARTIFICIAL TISSUE MODEL | ZHU, JIANJIAN | — |
| 18479843 | MICROFLUIDIC HANGING DROP CULTURE DEVICE FOR CULTURING CELL AGGREGATE | KIPOUROS, HOLLY MICHAELA | — |
| 18475303 | PHENOL DERIVATIVE-MODIFIED, TISSUE-DERIVED EXTRACELLULAR MATRIX DERIVATIVE FOR CONSTRUCTION OF ARTIFICIAL TISSUE | MELLER, MICHAEL V | — |
| 18355798 | DECELLULARIZED TISSUE-DERIVED EXTRACELLULAR MATRIX FUNCTIONALIZED WITH PHENOL DERIVATIVE AND USE THEREOF | THUESON, HANNA MARIE | — |
| 18347763 | ADIPOSE EXTRACELLULAR MATRIX-DERIVED SCAFFOLD FOR CULTURING ORGANOID AND PREPARING METHOD THEREOF | THUESON, HANNA MARIE | — |
| 18324601 | TISSUE GELL FOR TRANSPLANTATION USING DECELLULARIZED EXTRACELLULAR MATRIX AND METHOD OF PREPARING THE SAME | SCHUBERG, LAURA J | — |
| Art Unit | Apps |
|---|---|
| 1631 | 2 |
| 1638 | 2 |
| 1799 | 1 |
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18515269 | NON-ALCOHOLIC FATTY LIVER ARTIFICIAL TISSUE MODEL | ZHU, JIANJIAN | 1631 | §103DP | Final Rejection | — | Pending | Nov 21, 2023 |
| 18479843 | MICROFLUIDIC HANGING DROP CULTURE DEVICE FOR CULTURING CELL AGGREGATE | KIPOUROS, HOLLY MICHAELA | 1799 | §103 | Final Rejection | — | Pending | Oct 03, 2023 |
| 18475303 | PHENOL DERIVATIVE-MODIFIED, TISSUE-DERIVED EXTRACELLULAR MATRIX DERIVATIVE FOR CONSTRUCTION OF ARTIFICIAL TISSUE | MELLER, MICHAEL V | 1655 | §112 | Final Rejection | — | Pending | Sep 27, 2023 |
| 18355798 | DECELLULARIZED TISSUE-DERIVED EXTRACELLULAR MATRIX FUNCTIONALIZED WITH PHENOL DERIVATIVE AND USE THEREOF | THUESON, HANNA MARIE | 1638 | §103§112 | Final Rejection | — | Pending | Jul 20, 2023 |
| 18347763 | ADIPOSE EXTRACELLULAR MATRIX-DERIVED SCAFFOLD FOR CULTURING ORGANOID AND PREPARING METHOD THEREOF | THUESON, HANNA MARIE | 1638 | §102§103 | Final Rejection | — | Pending | Jul 06, 2023 |
| 18324601 | TISSUE GELL FOR TRANSPLANTATION USING DECELLULARIZED EXTRACELLULAR MATRIX AND METHOD OF PREPARING THE SAME | SCHUBERG, LAURA J | 1631 | §103 | Non-Final OA | — | Pending | May 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCellartgen Inc. has 6 pending office actions as of October 2026, spread across 4 art units and 5 examiners.
Hanna Marie Thueson has the most, with 2 of Cellartgen Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
